Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in children with beta-thalassemia major undergoing hematopoietic stem cell transplantation
PACTR202311877246623Phase 3Completed
- Sponsor
- Faculty of Medicine, Tanta University
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cyclophosphamide in beta thalassemia, sponsored by Faculty of Medicine, Tanta University. Primary endpoint: Acute graft-versus-host disease. Started Mar 2021; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on PACTR202311877246623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202311877246623.